Safety and clinical utility of long-term intravenous milrinone in advanced heart failure

American Journal of Cardiology

Volumn 80, Issue 1, 1997, Pages 61-64

  Mehra, Mandeep R ^a   Ventura, Hector O ^a   Kapoor, Charanjit ^a   Stapleton, Dwight D ^a   Zimmerman, David ^a   Smart, Frank W ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; HEPARIN; MILRINONE;

ADULT; AORTA BALLOON; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; CARDIOTONIC AGENTS; COHORT STUDIES; DOBUTAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; PYRIDONES; SURVIVAL RATE; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031195009     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00284-1     Document Type: Article

References (11)

1. 1. Alousi AA, Johnson DC. Pharmacology of the bipyridines: amrinone and milrinone. Circulation 1986;73(suppl III):III-10-111-24.
2. 2. Anderson JL, Baim DS, Fein SA, Goldstein RA, LeJemtel TH, Likoff NJ, Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. J Am Coll Cardiol 1987;9:711-722.
3. 3. Skoyles JR, Sherry KM, Price C. Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation. J Cardiothorac Vasc Anesth 1992;6:222-225.
4. 4. Sherry KM, Locke TJ. Use of milrinone in cardiac surgical patients. Cardiovasc Drugs Ther 1993;7:671-675.
5. 5. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
6. 6. Ross MP, Allen-Webb EM, Pappas JB, McGough EC. Amrinone-associated thrombocytopenia: pharmacokinetic analysis. Clin Pharmacol Ther 1993;53:661-667.
7. 7. Larsson R, Liedholm H, Andersson KE, Keane MA, Henry G. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol 1986;29;549-553.
8. 8. Unverferth DV, Blandford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour infusion. Am J Med 1980;69:262-266.
9. 9. Harden TK. Agonist-induced desensitization of the beta-receptor linked adenylate cyclase. Pharmacol Rev 1983;35:5-32.
10. 10. Kubo SH, Walter BA, John DH, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure: influence of systemic hemodynamics. Arch Intern Med 1987;147:1227-1230.
11. 11. Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:709-713.